Fate Therapeutics Inc (NASDAQ:FATE) currently has a daily average trading volume of 2.13M but it saw 2466987 shares traded in last market. With a market cap of 271.07M USD, the company’s current market price of $2.38 came falling about -7.03 while comparing to the previous closing price of $2.56. In past 52 weeks, the stock remained buoying in the range of price level as high as $8.83 and as low as $1.96. In the recent trading on the day, stock has struck highest price mark of $2.35 while lowest mark touched by it was $2.615.
Taking a look at 20-day trading activity of Fate Therapeutics Inc (FATE) gives us an average price of $2.46, while its current price level is -73.05% below from 52-week high level whereas it is 21.43% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.79 while that of 200 days or SMA-200 reads an average of $4.22. A closer look into the stock’s movement over the week reveals that its volatility is standing at 13.44% during that period while stretching the period over a month that increases to 15.55%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 44.46 which implies that the stock is in neutral territory.
Piper Sandler upgraded its recommendation for the stock as a “Overweight” from “Neutral” on June 17, 2024 while assigning a price target range of $4-$6. Wells Fargo issued its recommendations for the stock as it resumed the price target for the stock is $6.
Over the week, FATE’s stock price is moving -24.92% down while it is -11.19% when we observe its performance for the past one month. Year-to-date it is -36.36% down and over the past year, the stock is showing an upside performance of 0.42%.
Currently, Fate Therapeutics Inc’s total number of outstanding shares is 113.88M. Company’s return on investment (ROI) stands at -39.22% and return on equity (ROE) at -46.59%. Stock’s beta reads 1.93. Stock has a price to book (P/B) ratio of 0.75 while price to sale or P/S ratio amounts to 20.15. Its return on asset (ROA) is -34.32% on average.
